Mechanistic investigation of species-specific thyroid lesions induced by treatment with the histamine H1 antagonist temelastine (SK&F 93944) in rats

In vivo biliary excretion and in vitro cellular accumulation of thyroxine by rats or cultured rat hepatocytes treated with a novel histamine H1-receptor antagonist

“…This in turn results in the stimulation of the thyroid gland through increased circulating levels of TSH (Atterwill et al 1989). This effect is not mediated via enzyme induction, which has been reported for a variety of chemicals including polychlorinated biphenyls (Ba- ), tetrachlorodibenzo-p-dioxin (Henry and Gasiewicz 1987), an imidazole antimicrobial agent (Comer et al 1985) and a leukotriene antagonist (Sanders et al) but by a stimulation of the transport-mediated, active transport of T4 by the hepatocyte.…”

“…In oral toxicity studies lasting 6 or 12 months in Wistar rats temelastine produced alterations in thyroid morphology characterized by increased epithelial height and colloid depletion. Studies undertaken to investigate the thyroid changes showed that the clearance of T4 from the blood was increased in temelastine-treated rats, while in beagle dogs, which showed no evidence of treatment related thyroid histopathological changes, T4 clearance from the circulation remained unaffected by treatment (Atterwill et al 1989). Rats treated with temelastine also showed decreased circulatory T4 levels, increased thyroid follicular activity (as measured by radio-iodide accumulation) and elevated plasma thyroid stimulatory hormone (TSH) levels (Atterwill et al 1989).…”

In vivo biliary excretion and in vitro cellular accumulation of thyroxine by rats or cultured rat hepatocytes treated with a novel histamine H1-receptor antagonist

“…This in turn results in the stimulation of the thyroid gland through increased circulating levels of TSH (Atterwill et al 1989). This effect is not mediated via enzyme induction, which has been reported for a variety of chemicals including polychlorinated biphenyls (Ba- ), tetrachlorodibenzo-p-dioxin (Henry and Gasiewicz 1987), an imidazole antimicrobial agent (Comer et al 1985) and a leukotriene antagonist (Sanders et al) but by a stimulation of the transport-mediated, active transport of T4 by the hepatocyte.…”

“…In oral toxicity studies lasting 6 or 12 months in Wistar rats temelastine produced alterations in thyroid morphology characterized by increased epithelial height and colloid depletion. Studies undertaken to investigate the thyroid changes showed that the clearance of T4 from the blood was increased in temelastine-treated rats, while in beagle dogs, which showed no evidence of treatment related thyroid histopathological changes, T4 clearance from the circulation remained unaffected by treatment (Atterwill et al 1989). Rats treated with temelastine also showed decreased circulatory T4 levels, increased thyroid follicular activity (as measured by radio-iodide accumulation) and elevated plasma thyroid stimulatory hormone (TSH) levels (Atterwill et al 1989).…”

Trigger-Responsive Gene Transporters for Anticancer Therapy

“…Magnetic nanoparticles have been used as hyperthermia agents to kill cancer cells because the magnetic nanoparticles with higher specific absorption rate (SAR) values have the ability to generate heat in the presence of an alternative magnetic field (AMF) [ 166 , 167 ]. In addition, a recent study showed that along with delivering a therapeutic gene via magnetofection, they sensitized cells and then induced hyperthermia to completely destroy the cells [ 168 ].…”

In vivo biliary excretion and in vitro cellular accumulation of thyroxine by rats or cultured rat hepatocytes treated with a novel histamine H1-receptor antagonist

“…This in turn results in the stimulation of the thyroid gland through increased circulating levels of TSH (Atterwill et al 1989). This effect is not mediated via enzyme induction, which has been reported for a variety of chemicals including polychlorinated biphenyls (Ba- ), tetrachlorodibenzo-p-dioxin (Henry and Gasiewicz 1987), an imidazole antimicrobial agent (Comer et al 1985) and a leukotriene antagonist (Sanders et al) but by a stimulation of the transport-mediated, active transport of T4 by the hepatocyte.…”

“…In oral toxicity studies lasting 6 or 12 months in Wistar rats temelastine produced alterations in thyroid morphology characterized by increased epithelial height and colloid depletion. Studies undertaken to investigate the thyroid changes showed that the clearance of T4 from the blood was increased in temelastine-treated rats, while in beagle dogs, which showed no evidence of treatment related thyroid histopathological changes, T4 clearance from the circulation remained unaffected by treatment (Atterwill et al 1989). Rats treated with temelastine also showed decreased circulatory T4 levels, increased thyroid follicular activity (as measured by radio-iodide accumulation) and elevated plasma thyroid stimulatory hormone (TSH) levels (Atterwill et al 1989).…”

Trigger-Responsive Gene Transporters for Anticancer Therapy

“…Magnetic nanoparticles have been used as hyperthermia agents to kill cancer cells because the magnetic nanoparticles with higher specific absorption rate (SAR) values have the ability to generate heat in the presence of an alternative magnetic field (AMF) [ 166 , 167 ]. In addition, a recent study showed that along with delivering a therapeutic gene via magnetofection, they sensitized cells and then induced hyperthermia to completely destroy the cells [ 168 ].…”

In vivo biliary excretion and in vitro cellular accumulation of thyroxine by rats or cultured rat hepatocytes treated with a novel histamine H1-receptor antagonist

“…This in turn results in the stimulation of the thyroid gland through increased circulating levels of TSH (Atterwill et al 1989). This effect is not mediated via enzyme induction, which has been reported for a variety of chemicals including polychlorinated biphenyls (Ba- ), tetrachlorodibenzo-p-dioxin (Henry and Gasiewicz 1987), an imidazole antimicrobial agent (Comer et al 1985) and a leukotriene antagonist (Sanders et al) but by a stimulation of the transport-mediated, active transport of T4 by the hepatocyte.…”

“…In oral toxicity studies lasting 6 or 12 months in Wistar rats temelastine produced alterations in thyroid morphology characterized by increased epithelial height and colloid depletion. Studies undertaken to investigate the thyroid changes showed that the clearance of T4 from the blood was increased in temelastine-treated rats, while in beagle dogs, which showed no evidence of treatment related thyroid histopathological changes, T4 clearance from the circulation remained unaffected by treatment (Atterwill et al 1989). Rats treated with temelastine also showed decreased circulatory T4 levels, increased thyroid follicular activity (as measured by radio-iodide accumulation) and elevated plasma thyroid stimulatory hormone (TSH) levels (Atterwill et al 1989).…”

Trigger-Responsive Gene Transporters for Anticancer Therapy

“…Magnetic nanoparticles have been used as hyperthermia agents to kill cancer cells because the magnetic nanoparticles with higher specific absorption rate (SAR) values have the ability to generate heat in the presence of an alternative magnetic field (AMF) [ 166 , 167 ]. In addition, a recent study showed that along with delivering a therapeutic gene via magnetofection, they sensitized cells and then induced hyperthermia to completely destroy the cells [ 168 ].…”